Carregant...
A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?
[Image: see text] Roscovitine is an antitumor purine inhibitor of cyclin-dependent kinase CDK5, for which it displays submicromolar affinity. It reached phase IIb clinical trials in 2007. The search for analogues with improved kinase affinities led recently to an isomer, finisterine, having a nearly...
Guardat en:
| Publicat a: | ACS Omega |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Chemical Society
2017
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6044500/ https://ncbi.nlm.nih.gov/pubmed/30023695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.7b00471 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|